• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Consumer Cyclical·4937.T
Share

Waqoo Inc. Stocks

¥ 1570Last Updated 27.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

¥ 32.62M

¥ 1570
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 2005 and headquartered in Tokyo, Japan, Waqoo Inc. is primarily engaged in the formulation, production, and sale of cosmetic goods across the Japanese market. Its extensive lineup, sold under the HADA NATURE brand through its dedicated e-commerce platform, encompasses a variety of skincare items such as moisturizing gels, facial and hot cleansers, whitening serums and washes, general serums, protein-based products, and makeup bases. The company also offers hair care solutions, including shampoos, hair oils and masks, and head spa hair growth treatments. Furthermore, Waqoo Inc. diversifies its business by providing medical support services, particularly advertising, and specialized contract services for regenerative medicine, focusing on the processing of blood-derived and fat-derived stem cells.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.07.2026 23:27

Dior's owner reported an increase in sales of clothing and handbags for the first time in two years

27.07.2026 22:53

Nvidia formed an AI safety alliance following an accidental hack carried out by OpenAI

27.07.2026 22:30

Oncology drugs helped boost AstraZeneca's profits by 21%. Will the company expand its portfolio?

27.07.2026 22:13

Plata has appointed the former U.S. ambassador to Russia to its board of directors

27.07.2026 21:56

Bank of America announced the temporary closure of its positions in Kazakh government bonds

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026